DK2898890T3 - Stabilisering af viruspartikler - Google Patents

Stabilisering af viruspartikler Download PDF

Info

Publication number
DK2898890T3
DK2898890T3 DK15158279T DK15158279T DK2898890T3 DK 2898890 T3 DK2898890 T3 DK 2898890T3 DK 15158279 T DK15158279 T DK 15158279T DK 15158279 T DK15158279 T DK 15158279T DK 2898890 T3 DK2898890 T3 DK 2898890T3
Authority
DK
Denmark
Prior art keywords
stabilization
virus particles
virus
particles
Prior art date
Application number
DK15158279T
Other languages
Danish (da)
English (en)
Inventor
Jeffrey Drew
David Woodward
John Bainbridge
Amanda Corteyn
Original Assignee
Stabilitech Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1005521.8A external-priority patent/GB201005521D0/en
Priority claimed from GBGB1005520.0A external-priority patent/GB201005520D0/en
Priority claimed from GBGB1005497.1A external-priority patent/GB201005497D0/en
Priority claimed from GBGB1014962.3A external-priority patent/GB201014962D0/en
Priority claimed from GBGB1017647.7A external-priority patent/GB201017647D0/en
Priority claimed from GBGB1017648.5A external-priority patent/GB201017648D0/en
Application filed by Stabilitech Biopharma Ltd filed Critical Stabilitech Biopharma Ltd
Application granted granted Critical
Publication of DK2898890T3 publication Critical patent/DK2898890T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DK15158279T 2010-03-31 2011-03-31 Stabilisering af viruspartikler DK2898890T3 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB1005521.8A GB201005521D0 (en) 2010-03-31 2010-03-31 Stabilised liquid formulations of virus particles
EP10250706 2010-03-31
GBGB1005520.0A GB201005520D0 (en) 2010-03-31 2010-03-31 Stabilisation of viral particles
GBGB1005497.1A GB201005497D0 (en) 2010-03-31 2010-03-31 Method for stabilising viruses
GBGB1014962.3A GB201014962D0 (en) 2010-09-08 2010-09-08 Mehtod for stabilising viruses
GBGB1017647.7A GB201017647D0 (en) 2010-10-19 2010-10-19 Method for stabilising viruses
GBGB1017648.5A GB201017648D0 (en) 2010-10-19 2010-10-19 Liquid preparation containing stabilised viruses
EP11714373.5A EP2552465B1 (en) 2010-03-31 2011-03-31 Stabilisation of viral particles

Publications (1)

Publication Number Publication Date
DK2898890T3 true DK2898890T3 (da) 2019-11-25

Family

ID=43903999

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15158279T DK2898890T3 (da) 2010-03-31 2011-03-31 Stabilisering af viruspartikler
DK11714373.5T DK2552465T3 (en) 2010-03-31 2011-03-31 Stabilization of virus particles

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11714373.5T DK2552465T3 (en) 2010-03-31 2011-03-31 Stabilization of virus particles

Country Status (11)

Country Link
US (2) US10206960B2 (https=)
EP (2) EP2898890B1 (https=)
JP (1) JP5960120B2 (https=)
CN (1) CN102892424B (https=)
CA (1) CA2795013C (https=)
DK (2) DK2898890T3 (https=)
ES (2) ES2757591T3 (https=)
GB (1) GB2499479A (https=)
HU (2) HUE047521T2 (https=)
IL (1) IL221858A (https=)
WO (1) WO2011121306A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795050C (en) 2010-03-31 2018-05-22 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
WO2011121301A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
ES2757591T3 (es) 2010-03-31 2020-04-29 Stabilitech Biopharma Ltd Estabilización de partículas virales
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
EP3041504B1 (en) * 2013-09-03 2021-08-25 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
CA3048313A1 (en) * 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
GB2562241B (en) * 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
AR113996A1 (es) 2017-12-22 2020-07-08 Intervet Int Bv Vacunas líquidas de virus envueltos vivos
AU2019336940B2 (en) 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020245355A1 (en) * 2019-06-07 2020-12-10 Intervet International B.V. Mdbk irf3/irf7 knock out mutant cell and its use for vaccine production
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
JP7712284B2 (ja) 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
AR127944A1 (es) 2021-12-23 2024-03-13 Intervet Int Bv Vacunas líquidas estabilizadas de virus vivos

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US4980277A (en) 1987-10-16 1990-12-25 Cultor Ltd. Cryoprotectant solution and method
DE68908175T2 (de) 1988-05-27 1994-03-03 Centocor Inc Gefriergetrocknete formulierung für antikörperprodukte.
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
DE69032102T2 (de) 1989-08-15 1998-06-25 Massachusetts Inst Technology Stabilisierte impfstoffzusammensetzungen
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
RU2099418C1 (ru) 1991-11-21 1997-12-20 Лонца Аг Фрагмент днк, обеспечивающий использование бетаина, рекомбинантная плазмидная днк с фрагментом днк, обеспечивающим использование бетаина, штамм бактерий rhizobium/agrobacterium, предназначенный для стабильного хранения плазмиды с фрагментом днк, способ получения штамма бактерий
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
FR2698879B1 (fr) 1992-12-09 1995-01-13 Rhone Poulenc Biochimie gellules modifiées au niveau du catabolisme de la bétaïne, préparation et utilisations, notamment pour la production de métabolites ou d'enzymes.
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5965438A (en) 1995-06-07 1999-10-12 Phyton, Inc. Cryopreservation of plant cells
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US6037116A (en) * 1996-06-14 2000-03-14 Biostore New Zealand, Ltd. Compositions comprising betaine, sodium citrate and sodium chloride and methods for the preservation of biological materials
CA2242035C (en) 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
EP1032647B1 (en) 1997-11-26 2006-03-29 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DK1133316T3 (da) 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
AUPQ347199A0 (en) 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
JP2003535119A (ja) 2000-06-08 2003-11-25 パウダージェクト ワクチンズ，インコーポレーテッド 粉末組成物
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
WO2002101412A2 (en) 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
JP4527982B2 (ja) 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
JP2003261591A (ja) 2002-03-08 2003-09-19 Koji Hayade 凍結乾燥安定剤
WO2004002534A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
US20060228334A1 (en) * 2002-07-10 2006-10-12 Manuel Rosa-Calatrava Modified adenoviral fiber with ablated to cellular receptors
AU2003272174A1 (en) 2002-10-21 2004-05-04 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
JP2006521084A (ja) 2002-12-10 2006-09-21 シェーリング−プラウ・リミテッド イヌｒａｎｋｌならびにイヌｒａｎｋｌを調製および使用するための方法
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
EP2292642A1 (en) 2003-06-10 2011-03-09 Opal Therapeutics Pty Ltd Immunomodulating compositions, uses therefor and processes for their production
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
US20070111211A1 (en) 2003-12-30 2007-05-17 Virumar Pituach Tarkivim Ltd. Integrated viral complexes, methods of production thereof, vaccines containing same and methods of use thereof
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
KR101341359B1 (ko) 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
RS53890B1 (sr) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. Stabilizovan polimerni sistem za isporuku
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
EP1954308B1 (en) 2005-09-16 2011-09-07 Merial Ltd. Stabilizers for freeze-dried vaccines
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
CA2631714C (en) 2005-12-02 2014-09-16 Novartis Ag Nanoparticles for use in immunogenic compositions
CN101495136A (zh) 2006-02-15 2009-07-29 英克隆系统公司 抗体配制品
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
ES2286951B1 (es) 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
US20090053197A1 (en) 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
GB0705245D0 (en) * 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
CA2681567C (en) 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
US7879805B2 (en) 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
DE602008004351D1 (de) 2007-06-29 2011-02-17 Atrm Llc Flüssige proteinformulierungen mit gdf-5 zur verwendung bei erhöhten temperaturen
CA2693827A1 (en) 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
BRPI0911048A2 (pt) 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
US20110212127A1 (en) 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
MX2011003074A (es) 2008-09-24 2011-04-19 Stabilitech Ltd Metodo para conservar polipeptidos utilizando un azucar y polietilenimina.
WO2010146598A2 (en) 2008-11-07 2010-12-23 Serum Institute Of India Ltd. Stable, dried rotavirus vaccine, compositions and process for preparation thereof
EP2430195B1 (en) * 2009-05-11 2019-01-23 Biomatrica, INC. Compositions and methods for biological sample storage
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
CA2795050C (en) * 2010-03-31 2018-05-22 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
WO2011121301A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
ES2757591T3 (es) 2010-03-31 2020-04-29 Stabilitech Biopharma Ltd Estabilización de partículas virales
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions

Also Published As

Publication number Publication date
GB2499479A (en) 2013-08-21
CN102892424A (zh) 2013-01-23
CN102892424B (zh) 2015-04-01
HUE026885T2 (en) 2016-08-29
GB201216469D0 (en) 2012-10-31
JP2013524782A (ja) 2013-06-20
EP2552465B1 (en) 2015-04-22
AU2011234269A1 (en) 2012-10-04
ES2757591T3 (es) 2020-04-29
CA2795013A1 (en) 2011-10-06
EP2898890A1 (en) 2015-07-29
WO2011121306A1 (en) 2011-10-06
DK2552465T3 (en) 2015-07-27
EP2898890B1 (en) 2019-08-21
IL221858A (en) 2017-04-30
JP5960120B2 (ja) 2016-08-02
US10206960B2 (en) 2019-02-19
US20190307819A1 (en) 2019-10-10
HUE047521T2 (hu) 2020-04-28
EP2552465A1 (en) 2013-02-06
ES2543795T3 (es) 2015-08-21
CA2795013C (en) 2018-10-16
US20130129685A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
DK2898890T3 (da) Stabilisering af viruspartikler
IL269662A (en) Hepatitis C virus inhibitors
DK3725778T4 (da) Formuleringer af enzalutamid
DK2765990T3 (da) Faststofdispersion
DK3456831T3 (da) Målrettet modifikation af rottegenom
DK2398794T3 (da) Hæmmere af hepatitis C-virus
DK2771364T3 (da) Fremstilling af heterodimere proteiner
DK2603232T3 (da) Stabile formuleringer af linaclotid
DK3156056T3 (da) Farmaceutiske sammensætninger der består af sorbitanestere
IL224369B (en) Combinations of inhibitors for hepatitis c virus
CO7010824A2 (es) Inhibidores de aplicación viral
DK3418300T3 (da) Neutralisering af anti-influenza-a-virusantistoffer og anvendelser deraf
SG10201610753YA (en) Purification of virus like particles
IL225853A0 (en) Inhibitors of hepatitis c virus
IL227789A0 (en) Hepatitis c virus inhibitors
DK2555704T3 (da) Visning af hæmostatiske parametre
IL229270A0 (en) Hepatitis c virus inhibitors
DK2822568T3 (da) Anvendelser af caseinsammensætninger
DK2782565T3 (da) Anvendelse af aryl- og hetarylcarboxamider som endoparasiticider
DK2817334T3 (da) Fraktion i-iv-1 præcipitation af immunoglobiner fra plasma
EP2646052A4 (en) LYOPHILIZED VIRAL FORMULATIONS
DK2571843T3 (da) Forbedret fremstilling af chalcon-derivater
DK2554504T3 (da) Forbindelse af non-woven-materialer
DK2731572T3 (da) Forbedringer af indgivelsesanordninger
DK2838850T3 (da) Oprensning af titantetrachlorid